# N2003-01: Irinotecan, Temozolomide, and Cefixime in Treating Young Patients With Recurrent or Resistant Neuroblastoma

> **NCT00093353** · PHASE1 · COMPLETED · sponsor: **New Approaches to Neuroblastoma Therapy Consortium** · enrollment: 30 (estimated)

## Conditions studied

- Diarrhea
- Drug/Agent Toxicity by Tissue/Organ
- Neuroblastoma

## Interventions

- **DRUG:** cefixime
- **DRUG:** irinotecan hydrochloride
- **DRUG:** temozolomide

## Key facts

- **NCT ID:** NCT00093353
- **Lead sponsor:** New Approaches to Neuroblastoma Therapy Consortium
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-05
- **Primary completion:** 2006-07
- **Final completion:** —
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-04-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00093353

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00093353, "N2003-01: Irinotecan, Temozolomide, and Cefixime in Treating Young Patients With Recurrent or Resistant Neuroblastoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00093353. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*